Inspire Medical Systems Q4 preliminary revenue ~$192.4M (+40% YoY); FY2024 guidance $775-785M

Inspire Medical Systems, Inc.

2023-FY EPS reported -$0.72 revenue$624,799,000

Q4 2023 revenue expected $192.3-192.5M, ~40% increase over Q4 2022.
FY2023 revenue expected $624.6-624.8M, ~53% increase over FY2022.
Added 78 new U.S. centers in Q4, total 1,180; 13 new sales territories, total 287.
Initial FY2024 revenue guidance $775-785M, 24-26% growth over FY2023.
Company expects to report a profitable Q4 when full results are released Feb 6, 2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Inspire Medical Systems, Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue Revenue for the fourth quarter of 2023 is anticipated to be in the range of $192.3 million to $192.5 million. Guidance initiated.

Period: the fourth quarter and full year ended December 31, 2023
Revenue: Revenue for the fourth quarter of 2023 is anticipated to be in the range of $192.3 million to $192.5 million
Guidance: initiated
Result: preliminary results

Exact text from the filing

Inspire Medical Systems, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2023 and Provides Initial 2024 Guidance

View on SEC.gov

Browse all earnings releases →

Inspire Medical Systems, Inc. filing history →

Source: SEC EDGAR

accession 0001609550-24-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.